Identification and characterization of a novel cancer/testis antigen gene CAGE-1

Park, Saeyoung; Lim, Yeunhwan; Lee, Daeyeon; Cho, Bomsoo; Bang, Yung Jue; Sung, Sook-Whan; Kim, Hae Yeong; Kim, Dae Kee; Lee, Yun Sil; Song, Yeong Wook; Jeoung, Dooil

doi:10.1016/s0167-4781(02)00620-6

Cited by 63 publications

(38 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A unique class of tumor-associated antigens coded by the cancer testis (CT) gene family are being investigated as cancer biomarkers because of their aberrant expression in various types of cancer. 6 In this context, expression of several CT antigens, namely MAGE-A, 7 GAGE, 8 CAGE-1, 9 NY-ESO-1, 7 CRT2, 10 and SSX4, 11 have been reported in cervical cancer. However, humoral and cellular immune responses have been reported for only a few CT antigens.…”

mentioning

confidence: 99%

Sperm‐associated antigen 9 is a biomarker for early cervical carcinoma

Garg

Kanojia

Salhan

et al. 2009

Cancer

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Sperm‐associated antigen 9 is a biomarker for early cervical carcinoma

Garg

Kanojia

Salhan

et al. 2009

Cancer

View full text Add to dashboard Cite

show abstract

“…To identify the tumorassociated antigens capable of eliciting immune responses in autologous host is a major aim of tumor immunology. 1,2 Taking the advent of the discovery of a large number of tumor-associated antigens over the last decade, the tumor immunotherapy with various strategies has been approached using the identified genes and their encoding proteins. Cancer/testis (CT) antigens are a category of tumor antigens with normal expression restricted to male germ cells in the testis but not in other adult somatic tissues.…”

mentioning

confidence: 99%

“…CT antigens appear to be the ideal tumor-specific antigen in tumor immunotherapy because the spermatogenic cells do not express HLA molecules and are unable to induce autoimmune response in testis. 2 FATE/BJ-HCC-2 was originally identified as a testis-specific gene and we have recently identified it as a CT antigen-encoding gene, which maps to chromosome Xq28. 8,9 According to the late classification of CT antigens, the FATE/BJ-HCC-2 is nominated as FATE/CT43.…”

mentioning

confidence: 99%

Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues

Yang

Dong

Qiao

et al. 2005

Laboratory Investigation

View full text Add to dashboard Cite

FATE/BJ-HCC-2 is a newly identified cancer/testis (CT) antigen, which was detected in tumor tissues and testis. As previous studies of FATE/BJ-HCC-2 expression pattern were mainly based on messenger RNA (mRNA) analysis, it is necessary to investigate its actual protein expression pattern in tumor tissues for the evaluation of its application value. In this study, we produced specific polyclonal antibody (pAb) to the recombinant FATE/ BJ-HCC-2 protein and analyzed the FATE/BJ-HCC-2 antigen expression in normal and malignant tissues by the immunohistochemical approach. The results showed that there was no detectable FATE/BJ-HCC-2 antigen expressed in normal tissues except testis. In hepatocellular carcinoma (HCC) tissues, the FATE/BJ-HCC-2 antigen was detected in 20% (7/35) specimens. All samples that expressed the FATE/BJ-HCC-2 antigen were of poorly or moderately differentiated HCC. The stained antigen was located in the cytoplasm and the staining pattern showed heterogeneity from focal to more than 40% of the tumor cells. The FATE/BJ-HCC-2 antigen was also expressed in other tumor tissues. The results of [ 3 H]thymidine incorporation showed that FATE/BJ-HCC-2 protein enhanced tumor cell proliferation after transfection of FATE/BJ-HCC-2 gene in HCC cell line (Po0.01). This effect could be specifically blocked by anti-FATE/BJ-HCC-2 pAb. Serological screening showed that the antibody specific to the FATE/BJ-HCC-2 antigen was detected in 7.7% (4/52) patients. Notably, the four positive patients bore poorly or moderately differentiated HCC. FATE/BJ-HCC-2 mRNA transcript was detected in the peripheral blood mononuclear cells (PBMCs) of 46.67% patients whose resected HCC tissue samples were positive for FATE/BJ-HCC-2 mRNA, which implicated tumor cell dissemination in blood circulation and may relate to the metastasis of HCC. Thus, FATE/BJ-HCC-2 may be a valuable candidate CT antigen for polyvalent vaccines in tumor immunotherapy and an assisting diagnostic marker for prognosis of the disease.

show abstract

“…Les anticorps anti-NY-ESO-1 ont été ensuite détectés avec une fréquence variant entre 20 et 50 % dans d'autres cancers comme le cancer bronchique non à petites cellules [8], le cancer de la prostate [9], le cancer médullaire de la thyroïde [10] et le mélanome [11]. Par la suite, d'autres AAT ont été étudiés, comme la protéine CAGE-1 (cancer/testis antigen gene) dans le cancer du poumon [12], NY-BR-1, ING1 et hMena dans le cancer du sein [13,14], GLEA1 (glioma expressed antigen 1), GLEA2 et PHF3 (PHD finger protein 3) dans le glioblastome [15]. Il est intéressant de mentionner que certains de ces autoanticorps présentent un intérêt comme marqueurs diagnostiques précoces ou marqueurs prédictifs d'une réponse thérapeutique.…”

Section: Analyse Sérologique Des Banques D'expression D'adncunclassified